Recombinant Human Albumin:Delivering the Future of Type 2 Diabetes Medication
Drug Development and Delivery Issue: October 2012, Posted Date: 10/12/2012
Pub type: Veltis
"To ensure albumin half-life extension technology continues to meet the demands of innovative drug design, Novozymes has developed the next generation of albumin half-life extension technology. These albumin “variants” will open the door to longer dosing regimens for peptides such as GLP-1."